Display options
Cite
Al-Zamil HA, Ai-Twaijiri AS, Al-Mobeireek AF, et al. Effects of zafirlukast on the function of humanpolymorphonuclear neutrophil leukocytes in asthmatic patients: A prospective, controlled, in vitro study. Curr Ther Res Clin Exp. 2005;66(4):279-93doi: 10.1016/j.curtheres.2005.08.013.
Al-Zamil, H. A., Ai-Twaijiri, A. S., Al-Mobeireek, A. F., & Mustafa, A. A. (2005). Effects of zafirlukast on the function of humanpolymorphonuclear neutrophil leukocytes in asthmatic patients: A prospective, controlled, in vitro study. Current therapeutic research, clinical and experimental, 66(4), 279-93. https://doi.org/10.1016/j.curtheres.2005.08.013
Al-Zamil, Hana A, et al. "Effects of zafirlukast on the function of humanpolymorphonuclear neutrophil leukocytes in asthmatic patients: A prospective, controlled, in vitro study." Current therapeutic research, clinical and experimental vol. 66,4 (2005): 279-93. doi: https://doi.org/10.1016/j.curtheres.2005.08.013
Al-Zamil HA, Ai-Twaijiri AS, Al-Mobeireek AF, Mustafa AA. Effects of zafirlukast on the function of humanpolymorphonuclear neutrophil leukocytes in asthmatic patients: A prospective, controlled, in vitro study. Curr Ther Res Clin Exp. 2005 Jul;66(4):279-93. doi: 10.1016/j.curtheres.2005.08.013. PMID: 24672130; PMCID: PMC3964553.
Copy Download .nbib Format: NLM
Share it on

Curr Ther Res Clin Exp. 2005 Jul;66(4):279-93. doi: 10.1016/j.curtheres.2005.08.013.

Effects of zafirlukast on the function of humanpolymorphonuclear neutrophil leukocytes in asthmatic patients: A prospective, controlled, in vitro study.

Current therapeutic research, clinical and experimental

Hana A Al-Zamil, Ali S Ai-Twaijiri, Abdulla F Al-Mobeireek, Ali A Mustafa

Affiliations

  1. Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
  2. Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
  3. Department of Pharmacology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

PMID: 24672130 PMCID: PMC3964553 DOI: 10.1016/j.curtheres.2005.08.013

Abstract

BACKGROUND: Reactive oxygen species (ROSS) play an important role in the pathogenesis of asthma, and oxidative stress contributes to the initiation and worsening of inflammatory respiratory disorders (eg, asthma). Thus, antioxidant drugs may have a role in reducing or preventing damage in asthma.

OBJECTIVE: The aim of the study was to investigate the antioxidant effect of zafirlukast, a leukotriene receptor antagonist, in asthma.

METHODS: This prospective, controlled, in vitro study was conducted at KingKhalid University Hospital, Riyadh, Saudi Arabia. The generation of ROSS by polymorphonuclear neutrophil leukocytes (PMNs) in patients with mild to moderate asthma (forced expiratory volume in 1 second [FEVI], >70% of the predicted value) and healthy volunteers was assessed using chemiluminescence (CL) with phorbol 12-myristate 13-acetate (PMA) and opsonized zymosan (OPZ) in the presence of different concentrations of zafirlukast (1.25-60 μg/mL). The xanthine/xanthine oxidase (X-XOD) reaction was used to test the scavenging effect of the drug.

RESULTS: Six asthmatic patients (4 women, 2 men; mean age, 30.8 years; meanFEVI, 82.5% of the predicted value) and 8 healthy volunteers (4 women, 4 men; mean age, 28.8 years) were enrolled. A dose-dependent inhibition of the CL response was observed in both groups. However, patients with asthma required higher concentrations of zafirlukast to achieve an inhibitory effect similar to that in healthy controls. This difference was significant at concentrations of 20 to 60 μg/mL (all, P ≤ 0.05). When PMNs were challenged with OPZ, inhibition was also dose dependent in controls at all concentrations (all, P ≤ 0.05), but the inhibitory effect was not significant in the asthmatic patients at any concentration. The difference in the inhibitory effect between the 2 groups was significant at 30, 40, and 60 μg/mL (P < 0.02, <0.01, and <0.01, respectively). The mean (SEM) viability of the PMNs in the healthy controls was significantly affected only at the highest concentration compared with the control saline dose (86.5% [5.8%] vs 97.0% [8.%]; P < 0.05). No scavenging effect of zafirlukast was found using the X XOD system. Incubating PMA-stimulated cells with zafirlukast (5 and 10 μg/mL) for 10 minutes to 1 hour significantly increased the inhibitory effect of the drug by 15% to 46% (all, P < 0.001). When zafirlukast was tested for reversibility of its inhibitory effect on ROS production, its action was found to be irreversible at a concentration of 30 μg/mL (P < 0.001) and partially reversible at 60 μg/mL compared with the baseline saline control.

CONCLUSIONS: Zafirlukast inhibited ROS generation by PMNs in a dose-dependentmanner in asthmatic patients and healthy subjects. However, asthmatic patients required much higher concentrations compared with controls. The incubation of the stimulated cells with zafirlukast increased the inhibitory effect. This finding suggests that the therapeutic effect of zafirlukast in asthma may be in part related to its antioxidant action.

Keywords: asthmatic patients; chemiluminescence; healthy volunteers; polymorphonuclear leukocytes; reactive oxygen species; zafirlukast

References

  1. Nihon Rinsho. 2001 Oct;59(10):1979-85 - PubMed
  2. Immunology. 1988 May;64(1):51-9 - PubMed
  3. Ann Intern Med. 2000 Jan 18;132(2):97-104 - PubMed
  4. Ann Intern Med. 1997 Sep 15;127(6):472-80 - PubMed
  5. Clin Exp Allergy. 1999 Jun;29 Suppl 2:110-5 - PubMed
  6. J Clin Invest. 1999 Oct;104(7):837-43 - PubMed
  7. Dig Dis Sci. 1991 Feb;36(2):174-8 - PubMed
  8. Am J Respir Crit Care Med. 2001 Jan;163(1):226-33 - PubMed
  9. Chest. 1986 May;89(5):709-16 - PubMed
  10. Am J Respir Crit Care Med. 2001 Jan;163(1):266-72 - PubMed
  11. J Immunol Methods. 1997 Dec 15;210(1):1-10 - PubMed
  12. Chest. 1999 Feb;115(2):313-6 - PubMed
  13. Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):S238-46 - PubMed
  14. Biochem Biophys Res Commun. 2001 May 25;283(5):1003-6 - PubMed
  15. Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1273-6 - PubMed
  16. Drugs Exp Clin Res. 2002;28(4):133-45 - PubMed
  17. Curr Allergy Asthma Rep. 2004 May;4(3):217-23 - PubMed
  18. Immunology. 1987 Sep;62(1):53-9 - PubMed
  19. Immunology. 1986 Jul;58(3):479-87 - PubMed
  20. Clin Chem. 1979 Sep;25(9):1655-61 - PubMed
  21. Blood. 2001 Apr 15;97(8):2487-95 - PubMed
  22. Int Arch Allergy Appl Immunol. 1991;95(1):17-22 - PubMed
  23. Rev Pneumol Clin. 1997;53(3):119-27 - PubMed
  24. J Leukoc Biol. 1993 Apr;53(4):427-38 - PubMed
  25. Am Rev Respir Dis. 1982 Sep;126(3):449-51 - PubMed
  26. Prostaglandins. 1983 Feb;25(2):237-43 - PubMed
  27. Mol Pharmacol. 1999 Nov;56(5):1055-62 - PubMed
  28. Trends Pharmacol Sci. 1995 Sep;16(9):304-9 - PubMed
  29. FASEB J. 2004 May;18(7):842-4 - PubMed
  30. Clin Exp Allergy. 1993 Nov;23(11):926-33 - PubMed
  31. Scand J Clin Lab Invest Suppl. 1991;204:47-55 - PubMed
  32. Am J Respir Cell Mol Biol. 2000 Oct;23(4):572-7 - PubMed
  33. Clin Exp Allergy. 1998 Nov;28 Suppl 5:147-53; discussion 171-3 - PubMed
  34. Tohoku J Exp Med. 2004 Dec;204(4):249-56 - PubMed

Publication Types